4th
World ADC Summit
Harnessing the promise of empowered antibodies.
28 February - 1 March 2012
Frankfurt
John LambertEVP & CSO ImmunoGen
Manish GuptaAssociate Director, Clinical Pharmacology & Pharmacometrics Bristol-Myers Squibb
Antonio GualbertoGroup Head, Clinical Research Millennium
David SatijnAssociate Director Genmab
Mike SunAssociate Director Seattle Genetics
Puja SapraDirector Pfizer
Leonard ReynoSenior Vice President & CMO Agensys
Ulrich BrinkmannScientific Director Roche
Antibody drug conjugate experts are descending on Frankfurt in February as the European community convenes for its annual Summit. This year at the top of the agenda are issues surrounding European regulation, ADC characterisation & process development and drug safety & PK.
Through dedicated networking sessions and informative presentations, stakeholders new and old will refine how they can develop and implement a successful ADC program.
“The ADC Summit is very informative for people who are new to this field as well as the ADC experts. All of the talks were excellent”. Bristol-Myers Squibb
Working with pioneers at the likes of Pfizer, Roche, Takeda, Seattle Genetics, ImmunoGen, Astellas, Novartis, Millennium & Genmab to build the agenda, this year’s World ADC Summit will:
Download the brochure for more detail on all of these topics and make sure you check out the interactive pre-conference workshops on ADC pharmacokinetics, manufacturing and regulation.
1. Download the brochure to see more detail on the topics being covered
2. Stay updated by joining the LinkedIn community. Engage with over 800 of your peers – simply search “Antibody Drug Conjugates”
3. Check out our resource bank of exclusive reports, video interviews and speaker insights.
Something you want to share; white papers, articles or interested in speaking? Then let us know... just email any questions to info@hansonwade.com
Get the best rates by booking now to ensure your place at this unique meeting - Book online or call +44 (0)20 3141 8700.
John Lambert, Executive Vice President & Chief Scientific Officer, ImmunoGen
Paul Polakis, Director, Cancer Targets, Genentech
Hans Peter Gerber, Senior Director, Bioconjugates and Vascular Biology, Pfizer
Sanjeev Gangwar, Senior Director, Medicinal Chemistry, Bristol-Myers Squibb
Dennis Benjamin, Senior Director, Experimental Therapies, Seattle Genetics
Peter Senter, Vice President, Chemistry, Seattle Genetics
Alain Beck, Head of Physico-Chemistry Department, Pierre Fabre
“Excellent and detailed overview of the state of the art in ADC discovery. I would definitely come back for a second round. Nice job organising the event." Pfizer
“It was great opportunity to join ADC community and get the latest information. Thanks!" Daiichi Sankyo
“THE best opportunity to meet the pioneers in the field of ADC." AstraZeneca
“Overall, very well organised, I personally liked the workshop format the best”. Agensys
“The conference was fantastic. The group in general and presenters in particular were very open to new technologies and ideas.” Alvos Therapeutics
“The best conference for those actively involved in ADC." Spirogen